Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients.
A study was made on the inhibitory effect of triflusal (600 mg/d X 15) and acetylsalicylic acid (ASA, 400 mg/d X 15) on platelet aggregation in whole blood (WB) and platelet-rich plasma (PRP) induced by ADP (2.5 mumol/l), adrenaline (50 mumol/l), collagen (1 microgram/ml) and arachidonic acid (0.8 mmol/l), in 30 insulin-dependent diabetic patients without vascular complications. Determination was also made of the serum levels of thromboxane B2 (TxB2) and of the plasma levels of 6-keto-PGF1-alpha and of beta-thromboglobulin (B-TG). Both drugs exhibited higher inhibitory effects in WB than in PRP. In WB, a significant difference between triflusal and ASA was observed against ADP-induced aggregation (67% and 46% inhibition respectively, p less than 0.01). Both drugs strongly inhibit the formation of TxB2 in serum (85% and 99%, respectively). Triflusal does not significantly change the plasma levels of 6-keto-PGF1-alpha; ASA, by contrast, causes reduction of over 95% in those plasma levels. The plasma levels of B-TG were not modified by either of the drugs.
De la Cruz
J P
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
Pavia
J
J
Garcia-Arnes
J
J
Sanchez de la Cuesta
F
F
D000328:Adult; D001241:Aspirin / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011460:Prostaglandins F / Q000097:blood; D012459:Salicylates / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000097:blood; D001620:beta-Thromboglobulin / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; D011460:Prostaglandins F; D012459:Salicylates; D001620:beta-Thromboglobulin; C016167:triflusal; D013929:Thromboxane B2; D001241:Aspirin; C100006:prostaglandin F1